Nephrol Dial Transplant (1999) 14: 2178-2183
© 1999 European Renal Association-European Dialysis and Transplant Association
Preliminary Reports
Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease
Hôpital Manhès, Fleury-Mérogis, Ste-Genevieve-des-Bois, France
Correspondence and offprint requests to: Dr Gérard M. London, Hôpital Manhès, 8 Grande Rue, Fleury-Mérogis, Ste-Geneviève-des-Bois, F-91712, France.
Background. Because recent data demonstrated that the shortened survival and excess cardiovascular death of end-stage renal disease (ESRD) patients are predicted by hyperphosphataemia, we examined the haemodynamic alterations associated with high serum phosphorus levels in ESRD patients on haemodialysis.
Methods. Sixty-six ESRD patients were studied. Patients were separated arbitrarily into two groups, i.e. with predialysis serum phosphate <2 mmol/l (`normal' phosphate) and, serum phosphate >2 mmol/l (`high' phosphate). Cardiac and arterial function and structure were analysed by computer-assisted ultrasonography.
Results. Hyperphosphataemic patients were characterized by higher diastolic and mean blood pressures (P <0.05), and higher cardiac index (P<0.001) caused by an increased stroke index (P<0.05) and higher heart rate (P<0.01). The cardiac work index was significantly increased in patients with higher phosphate levels (P<0.01). Hyperphosphataemic patients tended to have a higher common carotid artery diameter (P=0.07), but similar carotid artery intima-media thickness, and lower carotid wall-to-lumen ratio (P<0.05) than patients with `normal' serum phosphorus. As a result of lower wall-to-lumen ratio in the presence of higher mean blood pressure, the carotid tensile stress was higher in hyperphosphataemic ESRD patients (P<0.05).
Conclusion These findings suggest that, in stable ESRD patients, hyperphosphataemia is associated with increased BP, hyperkinetic circulation, increased cardiac work, and high arterial tensile stress. These haemodynamic abnormalities could favour the development of cardiovascualr complications and contribute to high cardiovascular morbidity and mortality.
Keywords: arteriosclerosis; cardiac output; cardiac work; end-stage renal disease; hyperphosphataemia; hypertension
Please see also Editorial Comment by Amann et al. (pp. 2085–2087 in this issue).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. P. How, D. L. Mason, and A. H. Lau Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder Journal of Pharmacy Practice, June 1, 2008; 21(3): 196 - 213. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G. Achinger and J. C. Ayus Left Ventricular Hypertrophy: Is Hyperphosphatemia among Dialysis Patients a Risk Factor? J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S255 - S261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Moe and G. M. Chertow The Case against Calcium-Based Phosphate Binders Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 697 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Arici, S. Kahraman, G. Genctoy, B. Altun, U. Kalyoncu, A. Oto, S. Kirazli, Y. Erdem, U. Yasavul, and C. Turgan Association of mineral metabolism with an increase in cellular adhesion molecules: another link to cardiovascular risk in maintenance haemodialysis? Nephrol. Dial. Transplant., April 1, 2006; 21(4): 999 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nanovic Electrolytes and Fluid Management in Hemodialysis and Peritoneal Dialysis Nutr Clin Pract, April 1, 2005; 20(2): 192 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Peerce, L. Weaver, and R. D. Clarke Effect of 2'-phosphophloretin on renal function in chronic renal failure rats Am J Physiol Renal Physiol, July 1, 2004; 287(1): F48 - F56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. de Simone Left Ventricular Geometry and Hypotension in End-Stage Renal Disease: A Mechanical Perspective J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2421 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Goodman Medical management of secondary hyperparathyroidism in chronic renal failure Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii2 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Gutzwiller, D. Schneditz, A. R. Huber, C. Schindler, F. Gutzwiller, and C. E. Zehnder Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose Nephrol. Dial. Transplant., June 1, 2002; 17(6): 1037 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Locatelli, J. B. Cannata-Andia, T. B. Drueke, W. H. Horl, D. Fouque, O. Heimburger, and E. Ritz Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia Nephrol. Dial. Transplant., May 1, 2002; 17(5): 723 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Goodman, G. A. Hladik, S. A. Turner, P. W. Blaisdell, D. A. Goodkin, W. Liu, Y. M. Barri, R. M. Cohen, and J. W. Coburn The Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism J. Am. Soc. Nephrol., April 1, 2002; 13(4): 1017 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Goodman Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention Nephrol. Dial. Transplant., February 1, 2002; 17(2): 204 - 207. [Full Text] [PDF]
|
|
|
|
|
|
K. Amann, M.-L. Gross, G. M. London, and E. Ritz Hyperphosphataemia—a silent killer of patients with renal failure? Nephrol. Dial. Transplant., September 1, 1999; 14(9): 2085 - 2087. [Full Text] [PDF]
|
|